<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139458">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01779882</url>
  </required_header>
  <id_info>
    <org_study_id>BuCyBu study</org_study_id>
    <nct_id>NCT01779882</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT</brief_title>
  <official_title>Cyclophosphamide-Busulfan Versus Busulfan-Cyclophosphamide as Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: a Prospective Randomized Study to Assess Liver Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Zürich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the hypothesis, that the order of application of Busulfan
      (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem
      cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Liver toxicity</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Liver toxicity, assessed as absolute serum values of ASAT, ALAT, GGT, Alkaline Phosphatase, bilirubin at day 30.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>VOD</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence and severity of &quot;veno occlusive disease (VOD)&quot; at day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute graft-versus-host disease (GvHD)</measure>
    <time_frame>Day 30 and Day 100</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence and severity of acute GVHD, by organ (skin, liver, gut) at day 30 and day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Day 30 and Day 100</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Organ toxicity at day 30 and day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Day 30 and Day 100</time_frame>
    <safety_issue>No</safety_issue>
    <description>Survival, relapse and non-relapse mortality at day 30 and day 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative liver values</measure>
    <time_frame>Day 0, 10, 20 and 30</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Cumulative serum values of ASAT, ALAT, GGT, Alkaline Phosphatase, bilirubin for days 0, 10, 20 and 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum liver values</measure>
    <time_frame>Day 0, 10, 20 and 30</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Maximum serum values of ASAT, ALAT, GGT, AP, bilirubin at any time between day 0 and day 30</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cytokines measurement</measure>
    <time_frame>Day -8, 0, 10, 20 and 30</time_frame>
    <safety_issue>No</safety_issue>
    <description>To test the correlation between order of application of the conditioning regimen and the levels of proinflammatory cytokines as well as the correlation between levels of cytokines and development of acute GVHD, plasma samples will be collected at different time points.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacogenomics</measure>
    <time_frame>Day -8, -3 and 0</time_frame>
    <safety_issue>No</safety_issue>
    <description>The current hypothesis is that some functional polymorphisms of genes, which control important enzymes in BU and CY metabolism, contribute to the observed interindividual variability in toxicity after allogeneic HSCT.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Myeloid Leukemia</condition>
  <condition>Precursor Myeloid Neoplasms</condition>
  <condition>Lymphoid Neoplasms</condition>
  <arm_group>
    <arm_group_label>BU-CY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A (standard group): conditioning regimen with Busulfan (BU) followed by Cyclophosphamide (CY)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CY-BU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B (experimental group): conditioning regimen with Cyclophosphamide (CY) followed by Busulfan (BU)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.</description>
    <arm_group_label>BU-CY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.</description>
    <arm_group_label>CY-BU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients planned to undergo an allogeneic HSCT with myeloablative conditioning

          -  Age 18 - 65 years

          -  Myeloid leukemia respectively related precursor neoplasms (acute myeloid leukemia,
             chronic myeloid leukemia, myelodysplastic syndrome), or lymphoid neoplasms (acute
             lymphoblastic leukemia/lymphoma, mature B-/T-/NK-cell neoplasms).

          -  HLA-identical sibling donor or matched unrelated (min. 10/10 Ag matched)

          -  Patients with a history of hepatitis might be included, if no contraindication for
             HSCT exists.

          -  Patient must give written informed consent

        Exclusion Criteria:

          -  Indication other than myeloid leukemia respectively related precursor neoplasms, or
             lymphoid neoplasms.

          -  Severe liver damage for &gt; 2 weeks (bilirubin &gt; 3xULN or ASAT/ALAT &gt; 5xULN)

          -  HIV infection

          -  Donor other than HLA-identical sibling or min. 10/10 matched unrelated donor

          -  Pregnant or lactating women

          -  Lack of written informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Cantoni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Aarau, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sabine Gerull, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gayathri Nair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Zürich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves Chalandon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Geneva, Switzerland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jakob Passweg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathan Cantoni, MD</last_name>
    <phone>+41628389844</phone>
    <email>nathan.cantoni@ksa.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sabine Gerull, MD</last_name>
    <phone>+41613287683</phone>
    <email>sabine.gerull@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital, Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sabine Gerull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jakob Passweg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Yves Chalandon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gayathri Nair, MD</last_name>
      <phone>+41442551111</phone>
      <email>gayathri.nair@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Gayathri Nair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Cantoni N, Gerull S, Heim D, Halter J, Bucher C, Buser A, Tsakiris DA, Passweg J, Tichelli A, Stern M, Gratwohl A. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011 Mar;46(3):344-9. doi: 10.1038/bmt.2010.137. Epub 2010 Jun 14.</citation>
    <PMID>20548339</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 28, 2013</lastchanged_date>
  <firstreceived_date>January 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
